Literature DB >> 2842958

Synthesis of virus-specific RNA in permeabilized murine coronavirus-infected cells.

J L Leibowitz1, J R DeVries.   

Abstract

We have developed a permeabilized cell system for assaying mouse hepatitis virus-specific RNA polymerase activity. This activity was characterized as to its requirements for mono- and divalent cations, requirements for an exogenous energy source, and pH optimum. This system faithfully reflects MHV-specific RNA synthesis in the intact cell, with regard to both its time of appearance during the course of infection and the products synthesized. The system is efficient and the RNA products were identical to those observed in intact MHV-infected cells as judged by agarose gel electrophoresis and hybridization. Permeabilized cells appear to be an ideal system for studying coronavirus RNA synthesis since they closely mimic in vivo conditions while allowing much of the experimental flexibility of truly cell-free systems.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2842958      PMCID: PMC7131142          DOI: 10.1016/0042-6822(88)90147-x

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  40 in total

1.  Comparison of endogenous and exogenous RNA primers of poly(U) polymerase in rat hepatic ribosomes.

Authors:  T T Hayashi; K MacFarlane
Journal:  Biochem J       Date:  1979-03-01       Impact factor: 3.857

2.  Replicative RNA synthesis and nucleocapsid assembly in vesicular stomatitis virus-infected permeable cells.

Authors:  J H Condra; R A Lazzarini
Journal:  J Virol       Date:  1980-12       Impact factor: 5.103

3.  Replication of mouse hepatitis virus: negative-stranded RNA and replicative form RNA are of genome length.

Authors:  M M Lai; C D Patton; S A Stohlman
Journal:  J Virol       Date:  1982-11       Impact factor: 5.103

4.  Sequence relationships between the genome and the intracellular RNA species 1, 3, 6, and 7 of mouse hepatitis virus strain A59.

Authors:  W J Spaan; P J Rottier; M C Horzinek; B A van der Zeijst
Journal:  J Virol       Date:  1982-05       Impact factor: 5.103

5.  Characterization of two RNA polymerase activities induced by mouse hepatitis virus.

Authors:  P R Brayton; M M Lai; C D Patton; S A Stohlman
Journal:  J Virol       Date:  1982-06       Impact factor: 5.103

6.  Malignant rabbit fibroma virus causes secondary immunosuppression in rabbits.

Authors:  D S Strayer; E Skaletsky; G F Cabirac; P A Sharp; L B Corbeil; S Sell; J L Leibowitz
Journal:  J Immunol       Date:  1983-01       Impact factor: 5.422

7.  Malignant rabbit fibroma virus: observations on the culture and histopathologic characteristics of a new virus-induced rabbit tumor.

Authors:  D S Strayer; G Cabirac; S Sell; J L Leibowitz
Journal:  J Natl Cancer Inst       Date:  1983-07       Impact factor: 13.506

8.  Coronavirus mRNA synthesis involves fusion of non-contiguous sequences.

Authors:  W Spaan; H Delius; M Skinner; J Armstrong; P Rottier; S Smeekens; B A van der Zeijst; S G Siddell
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

9.  Isolation and identification of virus-specific mRNAs in cells infected with mouse hepatitis virus (MHV-A59).

Authors:  W J Spaan; P J Rottier; M C Horzinek; B A van der Zeijst
Journal:  Virology       Date:  1981-01-30       Impact factor: 3.616

10.  Characterization of leader-related small RNAs in coronavirus-infected cells: further evidence for leader-primed mechanism of transcription.

Authors:  R S Baric; S A Stohlman; M K Razavi; M M Lai
Journal:  Virus Res       Date:  1985-07       Impact factor: 3.303

View more
  12 in total

1.  Characterization of coronavirus RNA polymerase gene products.

Authors:  J Herold; S Siddell; J Ziebuhr
Journal:  Methods Enzymol       Date:  1996       Impact factor: 1.600

2.  Mitochondrial aconitase binds to the 3' untranslated region of the mouse hepatitis virus genome.

Authors:  S K Nanda; J L Leibowitz
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Mechanism of coronavirus transcription: duration of primary transcription initiation activity and effects of subgenomic RNA transcription on RNA replication.

Authors:  Y S Jeong; S Makino
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

4.  Colocalization and membrane association of murine hepatitis virus gene 1 products and De novo-synthesized viral RNA in infected cells.

Authors:  S T Shi; J J Schiller; A Kanjanahaluethai; S C Baker; J W Oh; M M Lai
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Nuclear localization of flavivirus RNA synthesis in infected cells.

Authors:  Pradeep Devappa Uchil; Anil V A Kumar; Vijaya Satchidanandam
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  The primary structure and expression of the second open reading frame of the polymerase gene of the coronavirus MHV-A59; a highly conserved polymerase is expressed by an efficient ribosomal frameshifting mechanism.

Authors:  P J Bredenbeek; C J Pachuk; A F Noten; J Charité; W Luytjes; S R Weiss; W J Spaan
Journal:  Nucleic Acids Res       Date:  1990-04-11       Impact factor: 16.971

7.  Specific binding of host cellular proteins to multiple sites within the 3' end of mouse hepatitis virus genomic RNA.

Authors:  W Yu; J L Leibowitz
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

Review 8.  Viral and cellular proteins involved in coronavirus replication.

Authors:  S T Shi; M M C Lai
Journal:  Curr Top Microbiol Immunol       Date:  2005       Impact factor: 4.291

9.  SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro.

Authors:  Martijn J van Hemert; Sjoerd H E van den Worm; Kèvin Knoops; A Mieke Mommaas; Alexander E Gorbalenya; Eric J Snijder
Journal:  PLoS Pathog       Date:  2008-05-02       Impact factor: 6.823

10.  The ns 4 gene of mouse hepatitis virus (MHV), strain A 59 contains two ORFs and thus differs from ns 4 of the JHM and S strains.

Authors:  S R Weiss; P W Zoltick; J L Leibowitz
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.